<DOC>
	<DOCNO>NCT00245141</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vincristine , dactinomycin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high energy x-ray kill tumor cell . Giving one drug ( combination chemotherapy ) radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give vincristine , dactinomycin , cyclophosphamide together without radiation therapy work treat patient embryonal rhabdomyosarcoma .</brief_summary>
	<brief_title>Vincristine , Dactinomycin , Cyclophosphamide With Without Radiation Therapy Treating Patients With Embryonal Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival rate patient low-risk embryonal rhadomyosarcoma treat shortened treatment schedule vincristine , dactinomycin , cyclophosphamide without radiotherapy . OUTLINE : Patients receive vincristine IV , dactinomycin IV , cyclophosphamide IV . Patients may also undergo radiotherapy . Treatment repeat every 3 week 8 course ( total 24 week ) absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 32 patient accrue study .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis embryonal rhabdomyosarcoma Primary operation pathological diagnosis within past 42 day The following variant eligible : Botryoid Spindle cell Anaplastic Meets 1 follow stage criterion : Stage I , clinical group I II ( N0 ) , define follow criterion : Favorable site , include orbit , head , neck ( exclude parameningeal site ) , genitourinary region ( exclude bladder/prostate site ) , biliary tract Tumor size Completely resect disease OR microscopic residual disease Lymph nod clinically negative Stage I , clinical group III ( N0 ) , define follow criterion : Favorable site Tumor size Gross residual disease allow ( orbit ) Lymph nod clinically negative Stage II , clinical group I ( N0 , Nx ) , define follow criterion : Unfavorable site ( site list favorable site ) Tumor ≤ 5 cm diameter Completely resect disease Lymph nod clinically negative OR lymph node involvement unknown PATIENT CHARACTERISTICS : Performance status 03 Life expectancy Not specify Hematopoietic WBC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 7.5 g/dL Hepatic SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Bile acid ≤ 2.5 time ULN Renal Creatinine base age follow : &lt; 0.8 mg/dL ( patient &lt; 5 year age ) &lt; 1.2 mg/dL ( patient 59 year age ) &lt; 1.5 mg/dL ( patient ≥ 10 year age ) Cardiovascular No severe heart disease Other Not pregnant nursing Must acceptable organ function age No uncontrolled infection No active malignancy No treat malignancy within past 5 year No hypersensitivity study drug No CharcotMarieTooth disease No chickenpox PRIOR CONCURRENT THERAPY : Chemotherapy No prior anticancer chemotherapy Endocrine therapy Prior anticancer steroid allow Radiotherapy No prior radiotherapy Other No concurrent pentostatin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
</DOC>